Примери за използване на Ameluz на Английски и техните преводи на Български
{-}
- 
                        Colloquial
                    
- 
                        Official
                    
- 
                        Medicine
                    
- 
                        Ecclesiastic
                    
- 
                        Ecclesiastic
                    
- 
                        Computer
                    
Ameluz contains.
How does Ameluz work?
Other information about Ameluz.
What Ameluz contains.
Do not use Ameluz.
Ameluz is only used on the skin.
How is Ameluz used?
What are the risks associated with Ameluz?
Why is Ameluz authorised in the EU?
How to use Ameluz.
Ameluz transiently increases phototoxicity.
How to store Ameluz.
What is Ameluz and what is it used for?
In this study a total of 138 patients were treated with Ameluz.
Ameluz should not be used on bleeding lesions.
In clinical phase III,a total of 436 patients were treated with Ameluz.
Ameluz can cause mucous membrane or eye irritation.
Breast-feeding should be discontinued for 12 hours after treatment with Ameluz.
Ameluz contains the active substance 5-aminolaevulinic acid.
Breast-feeding should be interrupted for 12 hours after application of Ameluz.
The use of Ameluz is not recommended if you use immunosuppressants.
Special care should be taken to avoid applying Ameluz into eyes or to mucous membranes.
If Ameluz is accidentally ingested, systemic toxicity is unlikely.
The side effects listed below have been reported when using Ameluz with a red-light lamp.
Ameluz contains the active substance 5-aminolaevulinic acid.
Daylight may not be sufficient for Ameluz daylight treatment during winter months in certain parts of Europe.
Ameluz is not recommended during pregnancy, due to insufficient knowledge.
The cosmetic outcome was assessed as very good orgood in 47.6% of the subjects in the Ameluz group compared to 25.0% of subjects in the placebo group.
Direct contact of Ameluz with the eyes or mucous membrane should be avoided.
After only 1 PDT complete patient clearance resulted in 61.8% vs. 9.4%, andcomplete lesion clearance in 84.2% vs. 22.0% for Ameluz and placebo treatment, respectively.